Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery by Else A. Aalbersberg, Tammie T. Cao, Martine M. Geluk-Jonker, Jeroen J. M. A. Hendrikx

Subjects: Get full text

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection by Frederik A. Verburg, Erik de Blois, Stijn Koolen, Mark W. Konijnenberg

Subjects: Get full text

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy by Dheeratama Siripongsatian, Attapon Jantarato, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Peerapon Kiatkittikul, Natphimol Boonkawin, Sukanya Yaset, Sirinsuda Somboon, Chanisa Chotipanich

Subjects: Get full text

Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy by Darren M. C. Poon, Darren M. C. Poon, William S. K. Cheung, Peter K. F. Chiu, Daniel H. S. Chung, John B. T. Kung, Daisy C. M. Lam, Angus K. C. Leung, Anthony C. F. Ng, Joe M. O’Sullivan, Jeremy Y. C. Teoh, Philip Y. Wu, Sam K. K. Wu, Philip W. K. Kwong

Subjects: “…[177Lu]Lu-PSMA-617…”
Get full text